- 2024, Volume 82 - Number 1
- Published: March 6, 2024
Omalizumab and new therapeutic targets in chronic spontaneous urticaria
Ana S. Pereira 1, Joana Xará 2, Duarte Flor 3, Margarida Gonçalo 4, 5
1 Serviço de Dermatovenereologia, Unidade Local de Saúde de Almada-Seixal, Almada, Portugal; 2 Department of Dermatology, University Hospital, Coimbra Local Health Unit and Faculty of Medicine, Coimbra, Portugal; 3 Department of Dermatology, University Hospital, Local Health Unit of Coimbra, Coimbra, Portugal; 4 Faculty of Medicine, University of Coimbra, Coimbra, Portugal; 5 Dermatology Clinic, Coimbra University Hospital, Coimbra, Portugal
Ana S. Pereira, Joana Xará, Duarte Flor, Margarida Gonçalo
La información completa de afiliaciones y autor de correspondencia está disponible en la versión original en PDF.
*Correspondence: Ana S. Pereira, Email not available
Abstract
Chronic spontaneous urticaria (CSU) is a common and distressing skin disease characterized by itchy wheals, angioedema, or both. There is currently no cure for CSU and symptomatic treatment is often insufficient. Omalizumab, a humanized anti-immunoglobulin (Ig) E monoclonal antibody, remains the only biological drug licensed for CSU, almost a decade after its approval. However, growing knowledge of the pathophysiological mechanisms of this disease has led to recent advances in its treatment, with several drugs in investigation both in pre-clinical and clinical settings. These include biologicals, such as dupilumab (anti-IL-4Rα), secukinumab (anti-IL-17), tezepelumab (anti-TSLP), ligelizumab (anti-IgE), lirentelumab (anti-Siglet 8), and barzovolimab (anti-cKIT), as well as “small molecules,” such as Bruton tyrosine kinase (BTK) inhibitors (remibrutinib) and a Mas-related G protein-coupled receptor X2 (MRGPRX2) antagonist. Here, we review the current and future therapeutic options for CSU, based on what is known about the pathogenesis of the disease.
